eligibility_summary
Inclusion: Adults 18–70 with advanced solid tumors post‑standard therapy, ECOG 0, >3‑mo life expectancy, adequate organ/hematologic function, tumor MSLN ≥50% membranous and PD‑L1+ on recent biopsy. Exclusion: prior MSLN/cell/gene/T‑cell therapy, active infection incl HIV/HBV/HCV/syphilis, autoimmune disease/transplant needing immunosuppression, major heart/lung/CNS disease, other malignancy (limited in‑situ exceptions), anticancer therapy <4 wks, pregnancy, investigator discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: αPD1‑MSLN‑CAR T cells—an autologous, gene‑engineered cellular immunotherapy (CAR T). Mechanism: patient T cells are modified with a chimeric antigen receptor that recognizes mesothelin (MSLN) on tumor cells to drive T‑cell activation and cytotoxicity, the product also provides anti‑PD‑1 activity to locally block the PD‑1/PD‑L1 checkpoint, aiming to prevent T‑cell exhaustion and enhance persistence/function in PD‑L1–positive tumors. Targets: mesothelin‑expressing tumor cells, PD‑1/PD‑L1 immune checkpoint in the tumor microenvironment, T‑cell activation pathways downstream of CAR signaling (CD3ζ/co‑stimulatory domains, unspecified). Phase I/II, single‑arm study in advanced solid tumors with high MSLN and PD‑L1 expression.